Spots Global Cancer Trial Database for HAIC Plus PD-1 Antibody vs HAIC Plus Sorafenib for Advanced HCC
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: HAIC Plus PD-1 Antibody vs HAIC Plus Sorafenib for Advanced HCC
Official Title: Hepatic Artery Infusion Chemotherapy Plus Programmed Cell Death Protein-1 (PD-1) Antibody vs Hepatic Artery Infusion Chemotherapy Plus Sorafenib for Advanced Hepatocellular Carcinoma
Study ID: NCT03780634
Conditions
Study Description
Brief Summary: The purpose of this study is to evaluate the efficacy and safety of hepatic artery infusion chemotherapy (HAIC) combined with Programmed Cell Death Protein-1 (PD-1) antibody compared with HAIC plus sorafenib in patients with advanced hepatocellular carcinoma (HCC)
Detailed Description: The results of our preliminary pilot study suggested that sorafenib combined with hepatic arterial infusion chemotherapy (HAIC) may improve the survivals for advanced hepatocellular (HCC). Programmed Cell Death Protein-1 (PD-1) antibody has been proved effective and safety for advanced HCC. There is no study about HAIC plus PD-1 antibody. Thus, the investigators carried out this prospective randomized control study to compare HAIC plus sorafenib and HAIC plus PD-1 antibody.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Cancer Center Sun Yat-sen University, Guangzhou, Guangdong, China
Guangzhou Twelfth People 's Hospital, Guangzhou, Guangdong, China
Kaiping Central Hospital, Kaiping, Guangdong, China
Contact Details
Name: Ming Shi, MD
Affiliation: Sun Yat-sen University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
